|
1
|
Chang SH and Hla T: Post-transcriptional
gene regulation by HuR and microRNAs in angiogenesis. Curr Opin
Hematol. 21:235–240. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kane NM, Howard L, Descamps B, Meloni M,
McClure J, Lu R, McCahill A, Breen C, Mackenzie RM, Delles C, et
al: Role of microRNAs 99b, 181a and 181b in the differentiation of
human embryonic stem cells to vascular endothelial cells. Stem
Cells. 30:643–654. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mishra RR, Kneitz S and Schartl M:
Comparative analysis of melanoma deregulated miRNAs in the medaka
and Xiphophorus pigment cell cancer models. Comp Biochem Physiol C
Toxicol Pharmacol. 163:64–76. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xu JQ, Liu P, Si MJ and Ding XY:
MicroRNA-126 inhibits osteosarcoma cells proliferation by targeting
Sirt1. Tumour Biol. 34:3871–3877. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bago-Horvath Z, Schmid K, Rössler F,
Nagy-Bojarszky K, Funovics P and Sulzbacher I: Impact of RANK
signalling on survival and chemotherapy response in osteosarcoma.
Pathology. 46:411–415. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guma SR, Lee DA, Ling Y, Gordon N and
Kleinerman ES: Aerosol interleukin-2 induces natural killer cell
proliferation in the lung and combination therapy improves the
survival of mice with osteosarcoma lung metastasis. Pediatr Blood
Cancer. 61:1362–1368. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ohba T, Cole HA, Cates JM, Slosky DA, Haro
H, Ando T, Schwartz HS and Schoenecker JG: Bisphosphonates inhibit
osteosarcoma-mediated osteolysis via attenuation of tumor
expression of MCP-1 and RANKL. J Bone Miner Res. 29:1431–1445.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rabinowicz R, Barchana M, Liphshiz I,
Futerman B, Linn S and Weyl-Ben-Arush M: Cancer incidence and
survival among children and adolescents in Israel during the years
1998 to 2007. J Pediatr Hematol Oncol. 34:421–429. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Salas SI, Jiguet-Jiglaire C, Campion L,
Bartoli C, Frassineti F, Deville JL, De Maues Paula A, Forest F,
Jézéquel P, Gentet JC and Bouvier C: Correlation between ERK1 and
STAT3 expression and chemoresistance in patients with conventional
osteosarcoma. BMC Cancer. 14:6062014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Valle J, Wasan H, Palmer DH, Cunningham D,
Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira
SP, et al: ABC-02 Trial Investigators: Cisplatin plus gemcitabine
versus gemcitabine for biliary tract cancer. N Engl J Med.
362:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Westlake SLI, Colebatch AN, Baird J, Kiely
P, Quinn M, Choy E, Ostor AJ and Edwards CJ: The effect of
methotrexate on cardiovascular disease in patients with rheumatoid
arthritis: a systematic literature review. Rheumatology (Oxford).
49:295–307. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin F, Wang Q, Yu W, Tang L, Zheng S, Sun
Y, Shen Z, Yao Y and Dong Y: Clinical analysis of Chinese limb
osteosarcoma patients treated by two combinations of methotrexate,
cisplatin, doxorubicin and ifosfamide. Asia Pac J Clin Oncol.
7:270–275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang TM, Qi SN, Zhao N, Yang YJ, Yuan HQ,
Zhang B and Jin S: Induction of apoptosis through
caspase-independent or caspase-9-dependent pathway in mouse and
human osteosarcoma cells by a new nitroxyl spin-labeled derivative
of podophyllotoxin. Apoptosis. 18:727–738. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ghayad SE and Cohen PA: Inhibitors of the
PI3K/Akt/mTOR pathway: new hope for breast cancer patients. Recent
Pat Anticancer Drug Discov. 5:29–57. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Markman B, Dienstmann R and Tabernero J:
Targeting the PI3K/Akt/mTOR pathway - beyond rapalogs. Oncotarget.
1:530–543. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gits CM, van Kuijk PF, Jonkers MB, Boersma
AW, Smid M, van Ijcken WF, Coindre JM, Chibon F, Verhoef C,
Mathijssen RH, et al: MicroRNA expression profiles distinguish
liposarcoma subtypes and implicate miR-145 and miR-451 as tumor
suppressors. Int J Cancer. 135:348–361. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guled M, Pazzaglia L, Borze I, Mosakhani
N, Novello C, Benassi MS and Knuutila S: Differentiating soft
tissue leiomyosarcoma and undifferentiated pleomorphic sarcoma: A
miRNA analysis. Genes Chromosomes Cancer. 53:693–702. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tafra R, Brakus SM, Vukojevic K, Kablar B,
Colovic Z and Saraga-Babic M: Interplay of proliferation and
proapoptotic and antiapoptotic factors is revealed in the early
human inner ear development. Otol Neurotol. 35:695–703. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu Y, Zhou Y, Feng X, Yang P, Yang J, An
P, Wang H, Ye S, Yu C, He Y and Luo H: Low expression of
microRNA-126 is associated with poor prognosis in colorectal
cancer. Genes Chromosomes Cancer. 53:358–365. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rabinowits G, Gercel-Taylor C, Day JM,
Taylor DD and Kloecker GH: Exosomal microRNA: A diagnostic marker
for lung cancer. Clin Lung Cancer. 10:42–46. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schaefer A, Jung M, Mollenkopf HJ, Wagner
I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G and Jung
K: Diagnostic and prognostic implications of microRNA profiling in
prostate carcinoma. Int J Cancer. 126:1166–1176. 2010.PubMed/NCBI
|
|
23
|
Guma SR, Lee DA, Yu L, Gordon N, Hughes D,
Stewart J, Wang WL and Kleinerman ES: Natural killer cell therapy
and aerosol interleukin-2 for the treatment of osteosarcoma lung
metastasis. Pediatr Blood Cancer. 61:618–626. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Anninga JK, Gelderblom H, Fiocco M, Kroep
JR, Taminiau AH, Hogendoorn PC and Egeler RM: Chemotherapeutic
adjuvant treatment for osteosarcoma: Where do we stand? Eur J
Cancer. 47:2431–2445. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rainusso N, Brawley VS, Ghazi A,
Gottschalk S, Rosen JM and Ahmed N: Immunotherapy targeting HER2
with genetically modified T-cells eliminates tumor-initiating cells
in osteosarcoma. Cancer Gene Ther. 19:212–217. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ando K, Heymann MF, Stresing V, Mori K,
Rédini F and Heymann D: Current therapeutic strategies and novel
approaches in osteosarcoma. Cancers (Basel). 5:591–616. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Luckasson R and Schalock RL: What's at
stake in the lives of people with intellectual disability? Part II:
Recommendations for naming, defining, diagnosing, classifying and
planning supports. Intellect Dev Disabil. 51:94–101. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Moritake H, Kamimura S, Kojima H,
Shimonodan H, Harada M, Sugimoto T, Nao-I N and Nunoi H:
Cytomegalovirus retinitis as an adverse immunological effect of
pulses of vincristine and dexamethasone in maintenance therapy for
childhood acute lymphoblastic leukemia. Pediatr Blood Cancer.
60:329–331. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang G, Li M, Zhu X and Yang C: Knockdown
of Akt sensitizes osteosarcoma cells to apoptosis induced by
cisplatin treatment. Int J Mol Sci. 12:2994–3005. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ell B and Kang Y: MicroRNAs as regulators
of bone homeostasis and bone metastasis. Bonekey Rep. 3:5492014.
View Article : Google Scholar : PubMed/NCBI
|
